Vertex still knows how to do what it does best
Vertex’s once-daily cystic fibrosis therapy succeeded in a pair of Phase 3 studies that compared it to Trikafta, a treatment that requires two doses per day. A third study found the drug…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a close read of the latest blockbuster deal, a look at Novartis’ multibillion-dollar gamble, and a reminder of what Vertex Pharmaceuticals does well.
What's Your Reaction?
